Endometrial Cancer Trial, Recruiting NCT04057924 Sponsor: University Hospital, Bordeaux Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04057924
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a moderate cervical cell abnormality (called CIN2), confirmed by a tissue sample (biopsy)
  • You are between 18 and 39 years old
  • Your cervical examination (colposcopy) gave a clear enough view to identify the affected area
  • You are covered by a social security or health insurance scheme
  • You have given your verbal agreement to take part and for your data to be used

Who may not be able to join:

  • You are currently pregnant
  • You have previously had a surgical procedure to remove abnormal cervical tissue (called a conization)
  • Abnormal glandular cells or cancer were unexpectedly found during a recent cervical smear test
  • You have received an HPV (human papillomavirus) preventative vaccine
  • You have an active infection currently requiring treatment, a history of HIV, or a condition that weakens your immune system (whether from birth or developed over time)
  • You are taking long-term steroids or medicines that suppress the immune system
  • You are currently under a legal protection measure relating to your ability to make decisions (confirm with trial site)
  • There are concerns that you may not be able to attend all required follow-up appointments over the long term

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 335 56 79 59 85

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 August 2019
Est. completion
1 September 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

rate of spontaneous regression of CIN2 at 2 years

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov